2022-502125-17-00已完成1 期
A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.5 个研究点 分布在 2 个国家目标入组 14 人开始时间: 2023年9月8日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14
- 试验地点
- 5
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (5)
Loading locations...
相似试验
招募中
不适用
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapyjRCT2031240308Nippon Boehringer Ingelheim Co., Ltd10
已完成
1 期
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy2023-508998-85-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.48
招募中
不适用
A study to test different doses of BI 1810631 in people with different types of advanced cancer (solid tumours with changes in the HER2 gene).NSCLCjRCT2031210165Boehringer Ingelheim96
已完成
1 期
A study to find the best dose of BI 836880 alone and in combination with BI 754091 in Japanese patients with different types of advanced cancerjRCT2080224681Nippon Boehringer Ingelheim Co., Ltd.21
招募中
1 期
A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors).2024-512504-19-00Boehringer Ingelheim International GmbH97